Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis.

ABSTRACT: Background: Pancreatic injury (pancreatitis, amylase/lipase elevation) is a rare adverse event of immune checkpoint inhibitors (ICIs). With the high number of clinical studies on ICIs, the incidence and characteristics of associated pancreatic injury (PI) need to be reevaluated. Methods: A systematic review and meta-analysis was conducted to assess the incidence of PI in cancer patients who received ICIs in randomized controlled trials (RCTs). PubMed, Embase, the ASCO, ESMO, and AACR conference proceedings before 1 April 2022, were investigated for relevant research. Results: 50 RCTs involving 35,223 patients were included. The incidence of ICIs-PI was 2.22% (95% CI = 1.94%-2.53%). The incidence of PI was 3.76% (95% CI = 1.84-7.67%) when combining two ICIs, which was h

SUBMITTER: Zhang T 

PROVIDER: S-EPMC9483178 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature